Ramsay Health Care Limited RESULTS BRIEFING

Year ended 30 June 2016

Christopher Rex, Managing Director 30 August 2016



Agenda

- 1. Group Operational and Financial Highlights
- 2. Segment Operational and Financial Highlights
- 3. Growth Strategy Update
- 4. Acquisitions & Strategic Developments
- 5. Outlook



Ramsay Health Care



Over
50 years
experience
in operating
hospitals



Operating across
6 countries



Admit over 3 million patients



Ranked in the top 5 private hospital operators in the world



Our comprehensive network



223 Hospitals



25,000 Hospital beds



38 Emergency departments



200 Pharmacies



1.4M Operations



63,000 Babies delivered



60,000 employees



Delivering Safe & Quality Healthcare



Commenced
longitudinal
international
studies of
patient
outcomes
following
treatment of low
back pain,
cataract surgery
and depression
and anxiety
(ICHOM)



Commenced rollout of Vanderbilt program (professional accountability) designed to manage behaviour that undermines a culture of quality and safety



All-time record achieved for lost time injury frequency rate (LTIFR) in Australia





Commenced
Antimicrobial
Stewardship
trial to improve
usage of
antibiotics in
hospitals



Following
France's lead, we
centralised our
clinical trials
programme in
Australia, which
will improve
access to latest
treatment and
outcomes for
patients across
our facilities







Group Operational and Financial Highlights



Financial Highlights

- Core NPAT up 16.8% to \$481.4 million
- Core EPS up 17.7% to 231.4 cents
- Group: Revenue up 18.1% to \$8.7 billion
 - Group EBIT up 11.6% to \$897.1 million
- Australia/Asia: Revenue up 8.8% to \$4.4 billion
 - EBIT up 11.6% to \$581.8 million
- United Kingdom: Revenue up 4.0% to £429.6 million
 - EBIT up 9.5% to £44.3 million
- France: Revenue up 27.3% to €2.2 billion
 - EBIT up 2.2% to €147.2 million
- Final Dividend 72.0 cents fully franked, up 19.0%, bringing the full-year dividend to 119.0 cents fully franked, up 17.8%



Operational Highlights

- Solid growth with all segments performing at or above expectations
- Integration of Ramsay Santé and Générale de Santé completed on 1 July 2015. Combined Group performing well
- Acquired a further nine hospitals in Lille, France (completed December 2015)
- Completed over \$300m in brownfield capacity expansions across the Group, opening over 500 beds and 26 operating theatres
- Commenced a pharmacy strategy which builds on our experience in the provision of hospital pharmacy services and enables us to care for patients beyond the hospital walls
- Exclusive contract to treat New Caledonian Medivac market (CAFAT) in our Sydney facilities
- Commenced four major studies with ICHOM during the year to investigate and benchmark patient outcomes following hospital admission



Group Financial Performance

Year Ended 30 June	2016	2015	Increase
Revenue	8,684.1	7,355.5	18.1%
EBITDAR	1,669.4	1,412.0	18.2%
EBITDA	1,268.9	1,106.3	14.7%
EBIT	897.1	803.9	11.6%
Core NPAT (1)	481.4	412.1	16.8%
Core EPS (2) (cents per share)	231.4¢	196.6¢	17.7%
Final Dividend – fully franked (cents per share)	72.0¢	60.5¢	19.0%
Full-year Dividend – fully franked (cents per share)	119.0¢	101.0¢	17.8%

Strong growth with all segments performing at or above expectations

Notes:

All numbers are in Australian dollars unless otherwise stated



⁽¹⁾ Core NPAT attributable to members of the parent is before non-core items. Générale de Santé has been consolidated from the acquisition date of 1 October 2014. The minority interests share of Générale de Santé Core NPAT has been removed in arriving at Core NPAT attributable to members of the parent

⁽²⁾ Core EPS is derived from core net profit after CARES dividends

Reconciliation To Statutory Reported Profit


Year Ended 30 June	2016	2015	Increase
Core NPAT	481.4	412.1	16.8%
Net non-core items, net of tax (1)	(31.1)	(26.6)	
Statutory Reported Net Profit after tax attributable to members of the Parent	450.3	385.5	16.8%

(1) Net non-core items (net of tax)	2016 \$m	2015 \$m
Deferred annual rent expense relating to UK hospitals	(15.9)	(16.6)
Profit/(Loss) on sale of non-current assets and impairment charges	(9.6)	3.0
Impact of change in French corporate income tax rate on deferred tax balances	13.5	-
Acquisition and development costs written off	(13.1)	(14.8)
Amortisation of intangibles	(3.1)	(2.9)
	(28.2)	(31.3)
Non controlling interest in non-core items	(2.9)	4.7
Net non-core items (net of tax)	(31.1)	(26.6)



Core NPAT & Core EPS

Compound Annual Growth Rate (CAGR)



- Core NPAT and Core EPS slightly ahead of upgraded (Feb'16) guidance
- Core NPAT up 16.8% to \$481.4 million
- Core EPS up 17.7% to 231.4 cents



Dividend Growth

Compound Annual Growth Rate (CAGR)



- Final dividend fully franked, up 19.0% on previous corresponding period
- Dividends for the full year up 17.8%, in line with growth in Core EPS of 17.7%
- Dividend payout ratio of approximately 50% of Core EPS maintained, balance reinvested back into the business



Core EPS & Dividend Growth


Compound Annual Growth Rate (CAGR) since listing





Leverage & Cash Management

Consolidated Balance Sheet Leverage Ratio*



- Strong operating cash flow with high cash conversion rate
- Strong balance sheet with financial flexibility to continue to fund:
 - the pipeline of brownfield capacity expansion
 - future acquisitions

→ Leverage* = Net Debt ÷ EBITDA



Segment Operational and Financial Highlights




Our current operating environments

Australia

- 1. Volumes and operations continue to trend upwards as expected due to the ageing and growing population
- 2. Increasing demand for quality services continues to drive brownfield investment
- 3. Private health care sector remains robust (47% of Australians with hospital treatment insurance)
- 4. Federal Government Private Health Sector Committee
- 5. Opportunities emerging to provide care beyond the hospital walls


Asia

- 1. Continued growth in demand
- 2. Acquisition multiples remain high
- 3. China remains an attractive opportunity





Financial Performance



Note: The above figures include Head Office

Australian Hospital Operations

- Strong organic growth on the back of strong admissions growth
- EBIT growth of 11.8% and margin uplift of 32 basis points
- Quality and strategically well-placed portfolio continues to produce good brownfield opportunities

Asian Hospital Operations

Robust operational performance in Malaysia and Indonesia



Our current operating environment


France

- Good volume growth across most major specialties
- 2. Excellent growth in emergency attendances up 8% on prior year
- 3. Strong quality portfolio of hospitals
 - leader in the market
- Currently a challenging political environment
- 5. French election set for May 2017





Financial Performance



- Integration of Ramsay Santé and Générale de Santé (RGdS) completed
- The combined group performed well in a challenging environment with EBITDA increasing by 14.6% to €274.0 million
- Ramsay Générale de Santé is well positioned in each of its regional market places to attract volume growth
- HPM has now been integrated into our French hospital portfolio and consolidates our leading position in the region.

^{*} In FY16 there is an additional 3mth contribution from RGdS (acquired Oct14) and a 6mth contribution from HPM (acquired Dec15)



Our current operating environment

UK

- Record referrals being achieved through *NHS Choose and Book* to Ramsay facilities
- Ramsay UK remains leader in NHS referrals
- 3. NHS over 75% of our patients and growing
- 4. Six Ramsay UK facilities scored in the top 15 hospitals in the UK (NHS and Independent Sector) after receiving 100% in latest survey (Feb 2016) by patients on the question of recommending the hospital to their friends and family
- 5. Brownfield opportunities continue to present
- 6. Some short term nurse staffing challenges across the industry, causing uplift in agency usage
- 7. Brexit





Financial Performance



- Ramsay's UK business continues to perform well with EBIT rising 9.5% to £44.3 million
- EBITDAR margins remain strong at 26.1%
- NHS patient admissions increased by 8.0%; now more than 75% of UK admissions



Growth Strategy Update



Delivering on our Growth Strategy

Creating shareholder value through our focused strategy

ORGANIC GROWTH

Underpinned by demographics, quality portfolio of hospitals, ongoing business improvement & volume expansion

BROWNFIELD CAPACITY **EXPANSION**

Unmet demand driving Ramsay's ongoing investment in capacity expansion

PUBLIC/PRIVATE COLLABORATIONS

Global focus on increasing private sector role in service provision for publically funded patients

ACQUISITIONS & STRATEGIC **DEVELOPMENTS**

Exploring acquisitions & strategic opportunities in existing & new markets Ramsay has proven it can export its management model Must add long-term value to shareholders



Brownfield developments

Overview

In FY16, across the Group Ramsay Health Care completed:



Over \$300M of developments



Over 500 beds



26 operating theatres



Major brownfields opened in FY16



Hollywood Private (90 beds; 6 theatres)



Cairns Private (56 beds)



Lake Macquarie **Emergency Department**



Joondalup Health Campus (30 bed paediatric wing)



St George Private Hospital (35 beds; 4 operating theatres)



Beleura Rehabilitation Centre (30 beds)



Masada Rehabilitation Centre (30 beds)



Shepparton Private Hospital (new mental health and rehabilitation wing)



New theatres at three hospitals in UK



New hospital completion



Wollongong Private Hospital opened in January 2016 with 151 beds and 10 theatres. The all new hospital has attracted new doctors and will stem the outflow of Wollongong patients to Sydney.



Pipeline of Developments

Brownfield developments due to open this calendar year:

- North Shore Private Hospital
- Peninsula Private Hospital
- New Farm Clinic
- Waverley Private Hospital
- Baringa Private Hospital



North Shore Private Hospital extension under construction



Peninsula Private Hospital



Pipeline of Developments (continued)

Over \$200M of future developments approved during FY16 including:

- Major expansion of St Andrew's Private Hospital in Ipswich, Greater Brisbane
- New Northside Clinic, Sydney
- Albert Road Clinic expansion, Melbourne
- Purchased land adjacent to Westmead Private Hospital & will commence master planning of this site
- In the UK additional operating theatres and a new day surgery centre

In addition, Ramsay will open a major new rehabilitation and mental health facility on the Gold Coast in early 2017



Architect Impression: New Northside Clinic



Acquisitions & Strategic Developments



Acquisitions & Strategic Developments

France

- Ramsay Générale de Santé acquired the HPM Group in December 2015
- The HPM Group includes nine hospitals in Lille, France

Australia

Ramsay appointed to operate hospital at the new Albury Wodonga Regional Cancer Centre

Asia

- Ramsay Sime Darby appointed to operate a hospital in Maldives
- Continue to investigate opportunities in China



Clinique Ambroise Paré



Albury Wodonga Regional Cancer Centre



Ramsay Pharmacy

- Over 200 hospital pharmacy dispensaries already operating across global hospital portfolio
- In process of establishing strategically located community pharmacies across Australia, concentrating initially in close proximity to our hospitals
- Specialised medication management
- 24/7 medicine on-call advice
- Community-based services and clinics
- Patient pathways from hospital to community
- Post discharge services for Ramsay hospital patients







Outlook



Outlook

- Demand for healthcare continues to be driven by population ageing, growth and expectations, emerging technology and the rising rate of chronic disease
- We continue to invest in our facilities and our people to ensure that we can meet the expectations of patients and doctors now and into the future
- Our pharmacy strategy presents us with new and exciting opportunities to care for patients in the community and develop services beyond the hospital walls
- We continue to investigate more opportunities internationally to grow our business, building on the success we have had thus far in the global healthcare marketplace
- Given strong industry fundamentals, continuing implementation of our successful growth strategy and barring unforeseen circumstances, Ramsay is targeting Core NPAT and Core EPS growth of 10% to 12% for FY2017



Questions

